News
The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.
David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback